PE20070113A1 - Derivados de quinolina y quinazolina como inhibidores de tirosinquinasas flt3 y trkb - Google Patents

Derivados de quinolina y quinazolina como inhibidores de tirosinquinasas flt3 y trkb

Info

Publication number
PE20070113A1
PE20070113A1 PE2006000650A PE2006000650A PE20070113A1 PE 20070113 A1 PE20070113 A1 PE 20070113A1 PE 2006000650 A PE2006000650 A PE 2006000650A PE 2006000650 A PE2006000650 A PE 2006000650A PE 20070113 A1 PE20070113 A1 PE 20070113A1
Authority
PE
Peru
Prior art keywords
dimetoxy
quinazolin
piperidin
trkb
flt3
Prior art date
Application number
PE2006000650A
Other languages
English (en)
Inventor
Nand Baindur
Michael David Gaul
Christian Andrew Baumann
Guozhang Xu
Bao-Ping Zhao
Alexander J Kim
Kevin Douglas Kreutter
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37101582&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070113(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20070113A1 publication Critical patent/PE20070113A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE q ES 0-2; p ES 0-1; Q ES NH, N(ALQUILO), O, O UN ENLACE DIRECTO; X ES N, C-CN, CH; Z ES NH, N(ALQUILO), CH2; B ES CICLOALQUILO, HETEROARILO, BENZOFUSIONADO DE 9-10 MIEMBROS, ENTRE OTROS; R1 Y R2 SON CADA UNO DE PREFERENCIA H, METOXI, 2-METOXI-ETOXI, ENTRE OTROS; R3 ES ALQUILO, ALCOXI, HALOGENO, NITRO, CICLOALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ESTER 1-(6,7-DIMETOXI-QUINAZOLIN-4-IL)-PIPERIDIN-4-ILICO DE ACIDO (4-ISOPROPIL-FENIL)-CARBAMICO; 2-[1-(6,7-DIMETOXI-QUINAZOLIN-4-IL)-PIPERIDIN-4-IL]-N-(4-ISOPROPIL-FENIL)-ACETAMIDA; N-[1-(6,7-DIMETOXI-QUINAZOLIN-4-IL)-PIPERIDIN-4-IL]-2-(4-ISOPROPIL-FENIL)-CARBAMICO; ENTRE OTROS. REFERIDA TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LA PROTEINA TIROSINA QUINASA, PARTICULARMENTE DE FLT3 (LIGANDO DE TIROSINQUINASA 3) Y/O TrkB (TIROSINQUINASA RECEPTORAS DE TIPO B), UTILES EN EL TRATAMIENTO DE CANCER Y OTROS DESORDENES PROLIFERATIVOS
PE2006000650A 2005-06-10 2006-06-09 Derivados de quinolina y quinazolina como inhibidores de tirosinquinasas flt3 y trkb PE20070113A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68938205P 2005-06-10 2005-06-10
US74732106P 2006-05-16 2006-05-16

Publications (1)

Publication Number Publication Date
PE20070113A1 true PE20070113A1 (es) 2007-02-09

Family

ID=37101582

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000650A PE20070113A1 (es) 2005-06-10 2006-06-09 Derivados de quinolina y quinazolina como inhibidores de tirosinquinasas flt3 y trkb

Country Status (17)

Country Link
US (1) US20070004763A1 (es)
EP (1) EP1899319A2 (es)
JP (1) JP2008543762A (es)
KR (1) KR20080028913A (es)
AR (1) AR057062A1 (es)
AU (1) AU2006258059A1 (es)
BR (1) BRPI0611621A2 (es)
CA (1) CA2611378A1 (es)
CR (1) CR9647A (es)
EA (1) EA200800014A1 (es)
EC (1) ECSP077998A (es)
GT (1) GT200600254A (es)
IL (1) IL187685A0 (es)
NO (1) NO20080168L (es)
PE (1) PE20070113A1 (es)
TW (1) TW200716598A (es)
WO (1) WO2006135649A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2066642A1 (en) * 2006-09-25 2009-06-10 Arete Therapeutics, INC. Soluble epoxide hydrolase inhibitors
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
AR102537A1 (es) 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
JP6903585B2 (ja) * 2015-03-13 2021-07-14 レスバーロジックス コーポレイション 補体関連疾患の治療のための組成物および治療方法
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
EP3394061B1 (en) 2015-12-23 2020-03-11 Merck Sharp & Dohme Corp. 6,7-dihydro-5h-pyrrolo[3,4-b]pyridin-5-one allosteric modulators of the m4 muscarinic acetylcholine receptor
CN109311816A (zh) * 2016-05-04 2019-02-05 百时美施贵宝公司 吲哚胺2,3-双加氧酶的抑制剂及其使用方法
EP3496715B1 (en) 2016-08-15 2021-11-03 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
US10414774B2 (en) 2016-08-15 2019-09-17 Merck Sharp & Dohme Corp. Compound useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolc disease
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112840A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
CN111372587B (zh) 2017-09-08 2024-01-09 里兰斯坦福初级大学理事会 Enpp1抑制剂以及它们用于治疗癌症的用途
EP3787629A4 (en) 2018-05-02 2022-01-05 Kinnate Biopharma Inc. INHIBITORS OF CYCLINE-DEPENDENT KINASES
WO2020006497A1 (en) 2018-06-29 2020-01-02 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
JPWO2020017569A1 (ja) * 2018-07-17 2021-12-02 日本ケミファ株式会社 Ｔ型カルシウムチャネル阻害剤
JP2022081710A (ja) * 2019-03-29 2022-06-01 ユーティアイ リミテッド パートナーシップ 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用
US20220226299A1 (en) * 2019-03-29 2022-07-21 Nippon Chemiphar Co., Ltd. Use of t-type calcium channel blocker for treating pruritus
CA3147422A1 (en) * 2019-07-17 2021-01-21 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
JP2023535096A (ja) * 2020-07-23 2023-08-15 シトシンラボ セラピューティクス カンパニー， リミテッド キナーゼ阻害活性を有する化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT344178B (de) * 1974-07-25 1978-07-10 Pfizer Verfahren zur herstellung von neuen chinazolinverbindungen und deren saeureadditionssalzen und optisch aktiven formen
JP3169188B2 (ja) * 1991-01-31 2001-05-21 杏林製薬株式会社 カルバミン酸誘導体及びその製造方法
EP1382603B1 (en) * 2001-04-26 2008-07-23 Eisai R&D Management Co., Ltd. Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof
MXPA05000081A (es) * 2002-06-27 2005-04-11 Schering Ag Quinolinas sustituidas antagonistas del receptor ccr5.
DK1678166T3 (da) * 2003-10-14 2009-11-09 Univ Arizona State Proteinkinaseinhibitorer

Also Published As

Publication number Publication date
IL187685A0 (en) 2008-08-07
TW200716598A (en) 2007-05-01
CR9647A (es) 2008-09-09
AR057062A1 (es) 2007-11-14
WO2006135649A3 (en) 2007-02-15
GT200600254A (es) 2007-01-12
JP2008543762A (ja) 2008-12-04
AU2006258059A1 (en) 2006-12-21
EA200800014A1 (ru) 2008-06-30
WO2006135649A2 (en) 2006-12-21
KR20080028913A (ko) 2008-04-02
NO20080168L (no) 2008-03-07
US20070004763A1 (en) 2007-01-04
BRPI0611621A2 (pt) 2010-09-21
EP1899319A2 (en) 2008-03-19
CA2611378A1 (en) 2006-12-21
ECSP077998A (es) 2008-01-23

Similar Documents

Publication Publication Date Title
PE20070113A1 (es) Derivados de quinolina y quinazolina como inhibidores de tirosinquinasas flt3 y trkb
PE20040647A1 (es) Inhibidores de cinasas de tirosina
PE20070076A1 (es) Aminopirimidinas como moduladores de quinasas
EA200800018A1 (ru) Аминопиримидины в качестве модуляторов киназы
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
PE20051171A1 (es) Inhibidores de proteina quinasas con estructura de 3-quinolincarbonitrilo
PE20060573A1 (es) Derivados de urea ciclicos sustituidos como inhibidores de proteinas quinasas
PE20091243A1 (es) Compuesto heterociclico fusionado
PE20091955A1 (es) Derivados de quinoxalin- y quinolin-carboxamida
PE20010741A1 (es) Derivados de piperazina como antagonistas de taquicininas
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
GT200600105A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos.
PE20070070A1 (es) Derivados de tienopiridina y tienopirimidina como agentes moduladores de tirosinquinasa
EA200700047A1 (ru) Новые алкильные производные в качестве метаботропных рецепторов глутамата
PE20060736A1 (es) DERIVADOS DE PIRROL COMO ANTAGONISTAS DE CRTh2
ATE557014T1 (de) Neue substituierte indolin-2-on-derivate und ihre verwendung als p38-mitogenaktivierte kinasehemmer
EA200700142A1 (ru) Замещенные гетероциклом циклические производные мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы
PE20090982A1 (es) Derivados de piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)
AR053109A1 (es) DERIVADOS DE PIPERIDINA Y PIPERAZINA, UN METODO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y SU USO EN LA ELABORACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR EL RECEPTOR DE QUIMIOQUINA CCR2.
PE20060770A1 (es) Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1
PE20081351A1 (es) Derivados de quinazolina como agentes anticancerigenos
PE20090876A1 (es) Nuevos derivados de 6-aril/heteroalquiloxi benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de cmet
AR051471A1 (es) Derivados de sulfonamida como moduladores del receptor de glugocorticoides
PE20070069A1 (es) Piperazin-piperidinas como antagonistas y agonistas del receptor 5-ht1a
TW200716599A (en) Alkylquinoline and alkylquinazoline kinase modulators

Legal Events

Date Code Title Description
FC Refusal